The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,222,431 in first-year total cost, median $611,216.
Most frequent study sections
- Special Emphasis Panel[ZTR1 RD-8 (01)]2
Most frequent institutions
- BAYLOR COLLEGE OF MEDICINE1
- GEORGE WASHINGTON UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Safety and Efficacy of Itacitinib in treatment of JAK/STAT pathway disorders with activating mutations1UG3TR003908-01 | FORBES, LISATORGERSON, TROY R | BAYLOR COLLEGE OF MEDICINE, TX | $647,617 | ZTR1 |
| 2021 | Emerging therapeutic candidates for rare maternally inherited mitochondrial diseases with shared etiologies1UG3TR003897-01 | CHIARAMELLO, ANNE ELIANEGROPMAN, ANDREA LYNNE | GEORGE WASHINGTON UNIVERSITY, DC | $574,814 | ZTR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.